Introduction
New insights: what is the relevance of HDL versus TRLs to residual risk?
Assessment of residual CV risk
Targeting residual risk: current approaches
Current pharmacotherapeutic strategies
Fibrates
Treatment/Trial [reference] | Daily dose (mg) | Patient criteria | Duration of follow-up | Key findings |
---|---|---|---|---|
Fenofibrate | ||||
ACCORD Lipid (n = 5,518) [46] | 1601 | Type 2 diabetes; Mean LDL-C ~2.07 mmol/L [80 mg/dL] on simvastatin (mean dose 22.4 mg/day) | 4.7 years | • No significant benefit on any CV outcomes for the total study population |
• For patients with marked atherogenic dyslipidaemia,2 there was ~30% reduction in the primary CV outcome versus simvastatin alone (12.4% versus 17.3%, p = 0.06 for interaction versus all other patients) | ||||
Niacin | ||||
ER niacin titrating to 1500-2000 | Patients with CVD with persistent atherogenic dyslipidaemia3 | Prematurely terminated; mean 3 years | • No significant outcomes benefit with ER niacin | |
• Methodological issues; inadequately powered, placebo contained a low-dose of niacin (50 mg/capsule), imbalance in concomitant LDL-C lowering therapy between groups | ||||
Median LDL-C on statin 1.91 mmol/L [74 mg/dL] | ||||
• For patients with marked atherogenic dyslipidaemia,4 there was a 36% relative reduction in the primary CV outcome (25.0% versus 16.7%, p = 0.032) | ||||
HPS2-THRIVE (n = 25,673) [63] | ER niacin/laropiprant 2000 | Patients with history of CVD | Median 3.9 years | • No significant outcomes benefit with ER niacin/laropiprant |
Mean lipid values at end of pre-randomisation phase (simvastatin 40 mg/day ± ezetimibe): | ||||
• Significant increases in diabetic complications, new-onset diabetes, infection, gastrointestinal effects (p < 0.0001), musculoskeletal, bleeding effects (p < 0.001) and skin adverse events (p = 0.026) with ER niacin/laropiprant | ||||
LDL-C 1.64 mmol/L [63 mg/dL] | ||||
HDL-C 1.14 mmol/L [44 mg/dL] | ||||
TG 1.43 mmol/L [125 mg/dL] | ||||
Omega-3 fatty acids | ||||
1800, EPA | High-risk patients with hypercholesterolaemia (total cholesterol ≥6.5 mmol/L [250 mg/dL]) | Mean 4.6 years | • 19% reduction in major coronary events (2.8% versus 3.5%, p = 0.011) with EPA + statin versus statin alone | |
Baseline mean LDL-C 4.6 mmol/L [180 mg/dL] on pravastatin 10 mg/day or simvastatin 5 mg/day | • A post hoc analysis showed a 53% relative reduction (p = 0.043) in patients with TG ≥1.7 mmol/L (150 mg/dL) and HDL-C <1.0 mmol/L (40 mg/dL) versus those without this dyslipidaemia | |||
ALPHA-OMEGA (n = 4,837) [67] | 400, EPA + DHA; | MI survivors, 85% on lipid-lowering therapy (mainly statins) | 40 months | • No significant effect on CV outcomes with any treatment versus placebo (best evidence-based treatment) |
2 g ALA; or both | ||||
Mean baseline lipids were | ||||
LDL-C 2.6 mmol/L [100 mg/dL] | ||||
HDL-C 1.28 mmol/L [49.5 mg/dL] | ||||
Median TG 1.69 mmol/L [150 mg/dL] | ||||
ORIGIN | 900 (465 EPA and 375 DHA) | Patients with or at risk of diabetes and at high CV risk | Median 6.2 years | • No significant effect on primary outcome (CV death) or secondary or other clinical outcomes |
(n = 12,536) [68] | ||||
Mean baseline lipids were | ||||
TC 4.9 mmol/L (190 mg/dL) | ||||
LDL-C 2.89 mmol/L (112 mg/dL) | ||||
HDL-C 1.19 mmol/L (46 mg/dL) | ||||
Median TG 1.58 mmol/L (140 mg/dL) |
Niacin
Omega-3 fatty acids
Ezetimibe
Do emerging therapies offer new hope?
Effects on atherogenic dyslipidaemia* | Other effects | Outstanding issues | |||
---|---|---|---|---|---|
Treatment group/example | Dose | Triglycerides | HDL-C | ||
[reference]; duration | |||||
SPPARMs: K-877 [81] | 100 μg BID | ↓70% | ↑18% | Improved safety profile (CV, renal and hepatic biomarkers) versus fenofibrate | ● Outcomes data, long-term safety |
12 weeks | |||||
Dual PPAR agonists | |||||
GFT505 (dual PPARα/δ) [84] | 80 mg OD | ↓17-25% | ↑8-9% | Improved safety profile (hepatic biomarkers) | ● Lower efficacy than current PPARα agonists |
4 weeks | ● Outcomes data, long-term safety | ||||
CETP inhibitors | |||||
Anacetrapib1[85] | 100 mg OD | ↓7% | ↑138% | Decreases in LDL-C (~40%), Lp(a) and apoB | ● Outcomes data, long-term safety |
24 weeks | |||||
Evacetrapib1[86] | 100 mg OD | NA | ↑~80% | Decreases in LDL-C (36%); data on other lipid effects NA | ● Outcomes data, long-term safety |
12 weeks | |||||
PCSK9 targeted therapy | |||||
Alirocumab1[87] | 150 mg every 2 weeks | ↓19% | ↑6% | Decreases in LDL-C (>60%); also Lp(a) and apoB | ● Outcomes data, long-term safety |
12 weeks | |||||
AMG 1451,2[88] | 140 mg every 2 weeks | ↓34% | ↑8% | Decreases in LDL-C (>60%), Lp(a) and apoB | ● Outcomes data, long-term safety |
12 weeks |